Until then, my family chooses to remain thankful for the available PF treatments and hopeful about the advancements that are ...

Treatment with Endeavor Biomedicines’ experimental oral therapy ENV-101 (taladegib) improved lung function in people with IPF ...

Columnist Samuel Kirton attended the Pulmonary Fibrosis Foundation's Summit 2025, where the group's five-year strategic plan was unveiled.

This Veterans Day, columnist Samuel Kirton writes about the PACT Act, which expanded coverage for veterans exposed to toxic substances.

BMS-986020 is an anti-fibrotic drug being developed by Bristol-Myers Squibb, and is chemically a lysophosphatidic acid (LPA) receptor antagonist. The drug, an oral formulation, is in clinical trials ...

The U.S. Food and Drug Administration (FDA) has granted breakthrough therapy designation to BMS-986278, Bristol Myers Squibb’s investigational therapy for progressive pulmonary fibrosis (PF).

The U.S. Food and Drug Administration (FDA) recently granted orphan drug designation to Calluna Pharma‘s CAL101 as a potential treatment for idiopathic pulmonary fibrosis (IPF). This designation is ...

The U.S. Food and Drug Administration (FDA) has granted its orphan drug designation to Alentis Therapeutics’ antibody-based therapy lixudebart (ALE.F02) for idiopathic pulmonary fibrosis (IPF). Orphan ...

[vc_row][vc_column][vc_column_text]Pulmonary fibrosis (PF) is a respiratory disease that causes the lung tissue to become thick and stiff. Over time, it turns into scar tissue, which is known as ...